1. Home
  2. ITOS vs CCIR Comparison

ITOS vs CCIR Comparison

Compare ITOS & CCIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITOS
  • CCIR
  • Stock Information
  • Founded
  • ITOS 2011
  • CCIR 2021
  • Country
  • ITOS United States
  • CCIR United States
  • Employees
  • ITOS N/A
  • CCIR N/A
  • Industry
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • CCIR
  • Sector
  • ITOS Health Care
  • CCIR
  • Exchange
  • ITOS Nasdaq
  • CCIR NYSE
  • Market Cap
  • ITOS 272.5M
  • CCIR 326.6M
  • IPO Year
  • ITOS 2020
  • CCIR 2024
  • Fundamental
  • Price
  • ITOS $7.48
  • CCIR $10.35
  • Analyst Decision
  • ITOS Strong Buy
  • CCIR
  • Analyst Count
  • ITOS 3
  • CCIR 0
  • Target Price
  • ITOS $21.33
  • CCIR N/A
  • AVG Volume (30 Days)
  • ITOS 268.0K
  • CCIR 9.0K
  • Earning Date
  • ITOS 03-05-2025
  • CCIR 01-01-0001
  • Dividend Yield
  • ITOS N/A
  • CCIR N/A
  • EPS Growth
  • ITOS N/A
  • CCIR N/A
  • EPS
  • ITOS N/A
  • CCIR N/A
  • Revenue
  • ITOS $35,000,000.00
  • CCIR N/A
  • Revenue This Year
  • ITOS $271.18
  • CCIR N/A
  • Revenue Next Year
  • ITOS N/A
  • CCIR N/A
  • P/E Ratio
  • ITOS N/A
  • CCIR N/A
  • Revenue Growth
  • ITOS N/A
  • CCIR N/A
  • 52 Week Low
  • ITOS $7.09
  • CCIR $9.98
  • 52 Week High
  • ITOS $18.75
  • CCIR $11.00
  • Technical
  • Relative Strength Index (RSI)
  • ITOS 43.24
  • CCIR N/A
  • Support Level
  • ITOS $7.30
  • CCIR N/A
  • Resistance Level
  • ITOS $7.91
  • CCIR N/A
  • Average True Range (ATR)
  • ITOS 0.32
  • CCIR 0.00
  • MACD
  • ITOS -0.02
  • CCIR 0.00
  • Stochastic Oscillator
  • ITOS 17.82
  • CCIR 0.00

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

About CCIR COHEN CIRCLE ACQUISITION CORP I

Cohen Circle Acquisition Corp I is a blank check company.

Share on Social Networks: